Lansforsakringar Fondforvaltning AB publ Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Lansforsakringar Fondforvaltning AB publ reduced its stake in Regeneron Pharmaceuticals by 4.2%, now holding 39,882 shares valued at approximately $25.29 million.
• Recent analyst upgrades have boosted Regeneron's price targets, with BMO Capital Markets raising theirs to $640 and Canaccord Genuity setting a target of $850.
• Regeneron recently declared a quarterly dividend of $0.88 per share, which is set to yield 0.6% annually, with a payout ratio of 8.87%.

Lansforsakringar Fondforvaltning AB publ lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,882 shares of the biopharmaceutical company's stock after selling 1,751 shares during the quarter. Lansforsakringar Fondforvaltning AB publ's holdings in Regeneron Pharmaceuticals were worth $25,294,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Pinney & Scofield Inc. acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 31 shares in the last quarter. Costello Asset Management INC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $27,000. Tompkins Financial Corp bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $32,000. Finally, Curat Global LLC bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $32,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded up $1.09 on Monday, reaching $580.70. 574,305 shares of the company's stock traded hands, compared to its average volume of 988,248. The stock's 50 day simple moving average is $557.26 and its two-hundred day simple moving average is $586.95. The stock has a market cap of $61.55 billion, a PE ratio of 14.63, a PEG ratio of 1.93 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,210.97. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The company had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the business posted $11.56 EPS. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Analyst Ratings Changes

REGN has been the subject of a number of recent research reports. BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research note on Monday, August 4th. Canaccord Genuity Group reiterated a "buy" rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Royal Bank Of Canada upped their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a report on Monday, August 4th. UBS Group reaffirmed a "neutral" rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Citigroup reissued a "buy" rating and set a $650.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.